About this FactMed analysis covering adverse side effect reports of ALMARL patients who developed ATELECTASIS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 4 individuals taking ALMARL reported ATELECTASIS to the FDA. A total of 227 ALMARL drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALMARL and ATELECTASIS. In doing so, we compare ALMARL with other drugs that cause ATELECTASIS, to help you evaluate whether or not ALMARL causes ATELECTASIS. Likewise, this page shows the most highly-reported side effects of ALMARL, so you can see if ATELECTASIS ranks among ALMARL's most well-known side effects.
Summary Statistics
Reports of ALMARL causing ATELECTASIS: 4
Reports of any side effect of ALMARL : 227
Percentage of ALMARL patients where ATELECTASIS is a reported side effect: 1.7621%

FDA reports of any drug causing ATELECTASIS : 8310
Average percentage for all medicated patients where ATELECTASIS is reported as a complication: 0.0521%

Physician opinion on ALMARL as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALMARL:
HYPERTENSION ( 76 patients )
PARKINSON'S DISEASE ( 8 patients )
ESSENTIAL TREMOR ( 6 patients )
ATRIAL FIBRILLATION ( 4 patients )
SCHIZOPHRENIA ( 2 patients )
TREMOR ( 2 patients )
ANGINA PECTORIS ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
PALPITATIONS ( 2 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 2 patients )
TACHYCARDIA ( 2 patients )
HYPERTROPHY ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with ATELECTASIS:

ZOMETA (2304 patients)
ASPIRIN (1755 patients)
AREDIA (1503 patients)
FOSAMAX (1426 patients)
VIOXX (1225 patients)
LASIX (1045 patients)
PREDNISONE (937 patients)
COUMADIN (892 patients)
LISINOPRIL (856 patients)
PROTONIX (814 patients)
AMBIEN (740 patients)
DEXAMETHASONE (739 patients)
PRILOSEC (641 patients)
OXYCONTIN (634 patients)
NEXIUM (631 patients)
ATIVAN (621 patients)
ZOLOFT (614 patients)
LIPITOR (606 patients)
VICODIN (604 patients)
LEVAQUIN (602 patients)
POTASSIUM CHLORIDE (598 patients)
NEURONTIN (596 patients)
DIGOXIN (576 patients)
ZOFRAN (562 patients)
FOLIC ACID (558 patients)
FUROSEMIDE (551 patients)
PAXIL (540 patients)
DECADRON (539 patients)
ACETAMINOPHEN (534 patients)
CELEBREX (532 patients)
ALBUTEROL (525 patients)
OXYCODONE HCL (515 patients)
PERCOCET (507 patients)
SYNTHROID (496 patients)
PREVACID (489 patients)
XANAX (476 patients)
HYDROCHLOROTHIAZIDE (471 patients)
REGLAN (450 patients)
ZOCOR (445 patients)
NORVASC (441 patients)
MORPHINE (438 patients)
AMOXICILLIN (436 patients)
LORTAB (426 patients)
ADVAIR DISKUS 100/50 (422 patients)
PLAVIX (418 patients)
OMEPRAZOLE (412 patients)
LORAZEPAM (397 patients)
REVLIMID (396 patients)
COMPAZINE (395 patients)
ARANESP (394 patients)
MULTI-VITAMINS (393 patients)
ATENOLOL (388 patients)
IBUPROFEN (387 patients)
LEXAPRO (380 patients)
LOVENOX (366 patients)
VITAMIN D (365 patients)
DILAUDID (362 patients)
VELCADE (361 patients)
WARFARIN SODIUM (361 patients)
THALIDOMIDE (353 patients)
PREDNISONE TAB (351 patients)
TOPROL-XL (343 patients)
TAXOTERE (343 patients)
SIMVASTATIN (341 patients)
METHOTREXATE (341 patients)
FEMARA (334 patients)
ALLOPURINOL (329 patients)
GABAPENTIN (327 patients)
XELODA (322 patients)
EFFEXOR (321 patients)
VANCOMYCIN (319 patients)
CALCIUM (315 patients)
COLACE (315 patients)
COREG (314 patients)
HEPARIN SODIUM INJECTION (308 patients)
METOPROLOL TARTRATE (299 patients)
LOPRESSOR (297 patients)
FENTANYL (294 patients)
RADIATION THERAPY (294 patients)
NUVARING (290 patients)
FLAGYL (288 patients)
AUGMENTIN '125' (287 patients)
NITROGLYCERIN (287 patients)
CHEMOTHERAPEUTICS NOS (284 patients)
PREMARIN (283 patients)
ZITHROMAX (275 patients)
CLINDAMYCIN (270 patients)
CIPROFLOXACIN (269 patients)
TAXOL (266 patients)
CYTOXAN (263 patients)
TAMOXIFEN CITRATE (263 patients)
ZYRTEC (262 patients)
LYRICA (261 patients)
CELEXA (260 patients)
FLUCONAZOLE (258 patients)
PEPCID (256 patients)
FLEXERIL (253 patients)
ALPRAZOLAM (252 patients)
CARBOPLATIN (251 patients)
ADRIAMYCIN PFS (249 patients)
ZANTAC (247 patients)
FASLODEX (247 patients)
CYCLOPHOSPHAMIDE (247 patients)
SPIRIVA (246 patients)
CHLORHEXIDINE GLUCONATE (246 patients)
VITAMIN E (246 patients)
NYSTATIN (244 patients)
SINGULAIR (244 patients)
CYMBALTA (243 patients)
MORPHINE SULFATE (242 patients)
CALCIUM CARBONATE (241 patients)
HEPARIN (238 patients)
ACYCLOVIR (238 patients)
LANTUS (237 patients)
DIOVAN (237 patients)
AVELOX (237 patients)
PROZAC (235 patients)
FLONASE (234 patients)
CEPHALEXIN (234 patients)
INSULIN (232 patients)
DURAGESIC-100 (230 patients)
TYLENOL (224 patients)
AROMASIN (223 patients)
MS CONTIN (220 patients)
NEUPOGEN (219 patients)
FLOMAX (218 patients)
VITAMIN B-12 (218 patients)
HERCEPTIN (217 patients)
DIFLUCAN (215 patients)
ASCORBIC ACID (215 patients)
ARIMIDEX (212 patients)
AVASTIN (212 patients)
VALIUM (212 patients)
LEVOTHYROXINE SODIUM (212 patients)
SEROQUEL (209 patients)
METFORMIN HCL (206 patients)
BENADRYL (206 patients)
ACCUTANE (204 patients)
FERROUS SULFATE TAB (203 patients)
SPIRONOLACTONE (200 patients)
TRAZODONE HCL (198 patients)
ALLEGRA (197 patients)
WELLBUTRIN (197 patients)
TEMAZEPAM (196 patients)
KLOR-CON (195 patients)
COMBIVENT (194 patients)
ZOLPIDEM (192 patients)
TYLENOL-500 (192 patients)
HYDROCODONE BITARTRATE (190 patients)
CIPRO (189 patients)
MELPHALAN HYDROCHLORIDE (188 patients)
PREDNISOLONE (187 patients)
PERIDEX (185 patients)
CLARITIN (185 patients)
REMICADE (182 patients)
MEGACE (181 patients)
PROMETHAZINE (180 patients)
KEFLEX (179 patients)
PROCRIT (179 patients)
METRONIDAZOLE (179 patients)
HYDROCODONE (179 patients)
ROCEPHIN (179 patients)
KLONOPIN (178 patients)
ZESTRIL (174 patients)
GEMZAR (174 patients)
NAVELBINE (174 patients)
MIRALAX (173 patients)
ELAVIL (173 patients)
PHENERGAN (171 patients)
DARVOCET-N 50 (171 patients)
VINCRISTINE (171 patients)
FAMOTIDINE (170 patients)
ATROVENT (169 patients)
CARDIZEM (168 patients)
AVANDIA (167 patients)
DOXYCYCLINE (166 patients)
METOPROLOL (164 patients)
FLUOROURACIL (163 patients)
PROCRIT /00909301/ (163 patients)
TYLENOL (CAPLET) (163 patients)
CLONIDINE (161 patients)
AMITRIPTYLINE HCL (161 patients)
POTASSIUM (160 patients)
ONDANSETRON (160 patients)
ALENDRONATE SODIUM (159 patients)
SOLU-MEDROL (158 patients)
NASONEX (158 patients)
EPOGEN (156 patients)
GLUCOPHAGE (156 patients)
MOTRIN (155 patients)
GLIPIZIDE (154 patients)
LACTULOSE (153 patients)
BACTRIM (152 patients)
ACTOS (152 patients)
DIAZEPAM (150 patients)
MULTI-VITAMIN (149 patients)
RESTORIL (148 patients)
YAZ (144 patients)
OXYCODONE (142 patients)
RANITIDINE (142 patients)
ETOPOSIDE (140 patients)
VALTREX (139 patients)
ALDACTONE (139 patients)
ULTRAM (138 patients)
ZETIA (138 patients)
AMIODARONE HCL (137 patients)
AMLODIPINE (137 patients)
LUPRON (136 patients)
VASOTEC (136 patients)
SENOKOT (135 patients)
Most common side effects for patients taking ALMARL:
DEPRESSED LEVEL OF CONSCIOUSNESS (20 patients)
HALLUCINATION (15 patients)
FALL (13 patients)
HYPOGLYCAEMIA (13 patients)
PYREXIA (12 patients)
TREMOR (12 patients)
DIARRHOEA (11 patients)
HEPATIC FUNCTION ABNORMAL (11 patients)
PNEUMONIA (10 patients)
DYSARTHRIA (10 patients)
BLOOD CREATINE PHOSPHOKINASE INCREASED (9 patients)
RENAL FAILURE ACUTE (9 patients)
LIVER DISORDER (9 patients)
CEREBRAL INFARCTION (8 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (8 patients)
DRUG INEFFECTIVE (8 patients)
RENAL IMPAIRMENT (8 patients)
HYPONATRAEMIA (8 patients)
INTERSTITIAL LUNG DISEASE (8 patients)
JAUNDICE (8 patients)
OEDEMA PERIPHERAL (8 patients)
CONDITION AGGRAVATED (7 patients)
DELIRIUM (7 patients)
DYSPHAGIA (7 patients)
DYSPNOEA (7 patients)
HYPOAESTHESIA (7 patients)
RHABDOMYOLYSIS (7 patients)
VOMITING (6 patients)
DELUSION (6 patients)
RESPIRATORY FAILURE (6 patients)
DYSKINESIA (6 patients)
SOMNOLENCE (6 patients)
HEPATIC NEOPLASM MALIGNANT (6 patients)
HYPERGLYCAEMIA (6 patients)
HYPOKALAEMIA (6 patients)
MOVEMENT DISORDER (6 patients)
MUSCULAR WEAKNESS (6 patients)
WHITE BLOOD CELL COUNT INCREASED (5 patients)
BLADDER CANCER (5 patients)
BLOOD ANTIDIURETIC HORMONE INCREASED (5 patients)
RESTLESSNESS (5 patients)
BLOOD OSMOLARITY DECREASED (5 patients)
PLEURAL EFFUSION (5 patients)
C-REACTIVE PROTEIN INCREASED (5 patients)
CONVULSION (5 patients)
RENAL DISORDER (5 patients)
VITH NERVE PARALYSIS (5 patients)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (5 patients)
INTESTINAL OBSTRUCTION (5 patients)
SEPSIS (5 patients)
ROAD TRAFFIC ACCIDENT (5 patients)
MUSCULOSKELETAL PAIN (5 patients)
NAUSEA (5 patients)
ANOREXIA (4 patients)
ATELECTASIS (4 patients)
ATRIAL FIBRILLATION (4 patients)
ATRIOVENTRICULAR BLOCK (4 patients)
BLOOD CREATININE INCREASED (4 patients)
BRADYCARDIA (4 patients)
CARDIAC FAILURE (4 patients)
CONSTIPATION (4 patients)
DECREASED APPETITE (4 patients)
DEHYDRATION (4 patients)
DIZZINESS (4 patients)
PLATELET COUNT DECREASED (4 patients)
PAIN (4 patients)
HYPERTENSION (4 patients)
HYPOTHYROIDISM (4 patients)
ILEUS (4 patients)
METABOLIC ACIDOSIS (4 patients)
SMALL INTESTINE CARCINOMA (4 patients)
URINE OSMOLARITY INCREASED (4 patients)
ABASIA (3 patients)
AGGRESSION (3 patients)
PRURITUS (3 patients)
ANAEMIA (3 patients)
PULMONARY ALVEOLAR HAEMORRHAGE (3 patients)
WHITE BLOOD CELL COUNT DECREASED (3 patients)
ASTHMA (3 patients)
BLOOD BILIRUBIN INCREASED (3 patients)
RENAL FAILURE (3 patients)
BLOOD PRESSURE DECREASED (3 patients)
BLOOD PRESSURE INCREASED (3 patients)
VASCULITIS (3 patients)
CAROTID ARTERY STENOSIS (3 patients)
THERAPEUTIC AGENT TOXICITY (3 patients)
CHILLS (3 patients)
CHROMATURIA (3 patients)
PETECHIAE (3 patients)
CHRONIC LYMPHOCYTIC LEUKAEMIA (3 patients)
PORIOMANIA (3 patients)
RENAL ARTERY STENOSIS (3 patients)
PANCYTOPENIA (3 patients)
DRUG ERUPTION (3 patients)
SUDDEN ONSET OF SLEEP (3 patients)
DRUG WITHDRAWAL SYNDROME (3 patients)
VERTIGO (3 patients)
EPILEPSY (3 patients)
FACE OEDEMA (3 patients)
VOLVULUS (3 patients)
GENERALISED OEDEMA (3 patients)
GINGIVAL BLEEDING (3 patients)
HAEMORRHAGE SUBCUTANEOUS (3 patients)
HALLUCINATION, VISUAL (3 patients)
PSYCHIATRIC SYMPTOM (3 patients)
HEART RATE DECREASED (3 patients)
HELICOBACTER TEST POSITIVE (3 patients)
HEPATITIS FULMINANT (3 patients)
HYPERKALAEMIA (3 patients)
HYPOTENSION (3 patients)
IDIOPATHIC THROMBOCYTOPENIC PURPURA (3 patients)
LOSS OF CONSCIOUSNESS (3 patients)
SENSORY DISTURBANCE (3 patients)
LYMPHOMA (3 patients)
MALAISE (3 patients)
MARKEDLY REDUCED DIETARY INTAKE (3 patients)
RENAL TUBULAR DISORDER (3 patients)
NEOPLASM MALIGNANT (3 patients)
SINUS ARREST (3 patients)
ABDOMINAL DISCOMFORT (2 patients)
ABDOMINAL PAIN (2 patients)
ACUTE MYELOID LEUKAEMIA (2 patients)
STOMACH MASS (2 patients)
PERSONALITY CHANGE (2 patients)
AGITATION (2 patients)
ALTERED STATE OF CONSCIOUSNESS (2 patients)
ANAPHYLACTOID REACTION (2 patients)
ANGER (2 patients)
PRODUCTIVE COUGH (2 patients)
RENAL CYST (2 patients)
APHASIA (2 patients)
ASTHENIA (2 patients)
ATRIOVENTRICULAR BLOCK COMPLETE (2 patients)
THIRST (2 patients)
PROSTATE CANCER (2 patients)
BLOOD AMYLASE INCREASED (2 patients)
BLOOD UREA INCREASED (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
SPEECH DISORDER (2 patients)
TUMOUR LYSIS SYNDROME (2 patients)
CEREBRAL HAEMORRHAGE (2 patients)
CHEST X-RAY ABNORMAL (2 patients)
COLON CANCER (2 patients)
COMA HEPATIC (2 patients)
COMPLETED SUICIDE (2 patients)
CONTUSION (2 patients)
PERFORMANCE STATUS DECREASED (2 patients)
DEFAECATION URGENCY (2 patients)
DEMENTIA ALZHEIMER'S TYPE (2 patients)
RASH PRURITIC (2 patients)
DIABETIC KETOACIDOSIS (2 patients)
DRUG INTERACTION (2 patients)
DRUG LEVEL INCREASED (2 patients)
DYSPEPSIA (2 patients)
DYSSTASIA (2 patients)
ELECTROCARDIOGRAM QT PROLONGED (2 patients)
STEVENS-JOHNSON SYNDROME (2 patients)
EPULIS (2 patients)
EXTRAOCULAR MUSCLE PARESIS (2 patients)
FACIAL PARESIS (2 patients)
FEAR (2 patients)
FEBRILE NEUTROPENIA (2 patients)
FEMORAL NECK FRACTURE (2 patients)
FOOT FRACTURE (2 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (2 patients)
GANGRENE (2 patients)
GASTRIC ULCER HAEMORRHAGE (2 patients)
GINGIVAL HYPERTROPHY (2 patients)
GLOSSOPTOSIS (2 patients)
PLEURISY (2 patients)
PHRENIC NERVE PARALYSIS (2 patients)
HAEMATEMESIS (2 patients)
HAEMATURIA (2 patients)
HAEMOGLOBIN DECREASED (2 patients)
POLLAKIURIA (2 patients)
ORAL INTAKE REDUCED (2 patients)
HEPATIC CYST (2 patients)
HEPATIC ENCEPHALOPATHY (2 patients)
HEPATITIS (2 patients)
HYPERREFLEXIA (2 patients)
HYPERTONIA (2 patients)
HYPERURICAEMIA (2 patients)
RASH PAPULAR (2 patients)
INITIAL INSOMNIA (2 patients)
RETINAL OEDEMA (2 patients)
INTESTINAL FUNCTIONAL DISORDER (2 patients)
RESPIRATION ABNORMAL (2 patients)
IRRITABILITY (2 patients)
RIB FRACTURE (2 patients)
LEG AMPUTATION (2 patients)
LYMPHADENOPATHY (2 patients)
METABOLIC ALKALOSIS (2 patients)
ORAL HERPES (2 patients)
TAKAYASU'S ARTERITIS (2 patients)
MOUTH HAEMORRHAGE (2 patients)
UNRESPONSIVE TO STIMULI (2 patients)
TOXIC SKIN ERUPTION (2 patients)
NEPHROLITHIASIS (2 patients)
SUICIDE ATTEMPT (2 patients)
VENTRICULAR FIBRILLATION (2 patients)
NEUTROPHIL COUNT DECREASED (2 patients)
UPPER RESPIRATORY TRACT INFECTION (2 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (2 patients)
SHOCK HAEMORRHAGIC (2 patients)
ABDOMEN CRUSHING (1 patients)
CARDIAC FAILURE CONGESTIVE (1 patients)
EOSINOPHILIC PNEUMONIA ACUTE (1 patients)
ESSENTIAL TREMOR (1 patients)
WRONG TECHNIQUE IN DRUG USAGE PROCESS (1 patients)
FUNGAL INFECTION (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALMARL


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ATELECTASIS and ALMARL, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALMARL, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALMARL. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALMARL experts. If you are a healthcare provider experienced in prescribing ALMARL, please register here.

Your online appointment book for Pasadena Rentals & Services

© 2014 FactMed, Inc
Privacy Policy
Terms of Use